IN2015DN04089A - - Google Patents
Info
- Publication number
- IN2015DN04089A IN2015DN04089A IN4089DEN2015A IN2015DN04089A IN 2015DN04089 A IN2015DN04089 A IN 2015DN04089A IN 4089DEN2015 A IN4089DEN2015 A IN 4089DEN2015A IN 2015DN04089 A IN2015DN04089 A IN 2015DN04089A
- Authority
- IN
- India
- Prior art keywords
- enantiomers
- signifies
- alkyl alkylaryl
- alkylheteroaryl
- proviso
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261726119P | 2012-11-14 | 2012-11-14 | |
| PCT/PT2013/000065 WO2014077715A1 (en) | 2012-11-14 | 2013-11-14 | 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN04089A true IN2015DN04089A (sr) | 2015-10-09 |
Family
ID=49759506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4089DEN2015 IN2015DN04089A (sr) | 2012-11-14 | 2013-11-14 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US9604970B2 (sr) |
| EP (1) | EP2919780B1 (sr) |
| JP (1) | JP6373275B2 (sr) |
| KR (1) | KR102259938B1 (sr) |
| CN (1) | CN105025895B (sr) |
| AU (1) | AU2013345494B2 (sr) |
| BR (1) | BR112015010969B1 (sr) |
| CA (1) | CA2890920C (sr) |
| CY (1) | CY1120953T1 (sr) |
| DK (1) | DK2919780T3 (sr) |
| ES (1) | ES2693025T3 (sr) |
| HK (1) | HK1215393A1 (sr) |
| HR (1) | HRP20181651T1 (sr) |
| IN (1) | IN2015DN04089A (sr) |
| LT (1) | LT2919780T (sr) |
| MX (1) | MX355422B (sr) |
| PL (1) | PL2919780T3 (sr) |
| PT (1) | PT2919780T (sr) |
| RS (1) | RS57874B1 (sr) |
| RU (1) | RU2718055C2 (sr) |
| SI (1) | SI2919780T1 (sr) |
| TR (1) | TR201815850T4 (sr) |
| WO (1) | WO2014077715A1 (sr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021005623A1 (en) * | 2019-07-08 | 2021-01-14 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2919780T3 (en) | 2012-11-14 | 2018-11-26 | Bial Portela & Ca Sa | 1,3-Dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury |
| GB201810395D0 (en) | 2018-06-25 | 2018-08-08 | Bial Portela & Ca Sa | Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0623107B2 (ja) * | 1990-11-16 | 1994-03-30 | 帝人株式会社 | プロスタサイクリン類を有効成分とする薬学的組成物 |
| EP0757677B1 (en) * | 1994-04-26 | 2003-06-18 | Syntex (U.S.A.) LLC | Benzocyclohexylimidazolethione derivatives |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US7125904B2 (en) | 2002-10-11 | 2006-10-24 | Portela & C.A., S.A. | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation |
| CA2412856A1 (en) * | 2002-11-27 | 2004-05-27 | Frederic Bodin | Pharmaceutical composition for the treatment of pulmonary arterial hypertension |
| GB0600709D0 (en) | 2006-01-13 | 2006-02-22 | Portela & Ca Sa | Drug combinations |
| GB0610804D0 (en) * | 2006-05-31 | 2006-07-12 | Portela & Ca Sa | New crystal forms |
| GB0700635D0 (en) | 2007-01-12 | 2007-02-21 | Portela & Ca Sa | Therapy |
| WO2008137148A2 (en) * | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Methods and compositions for treating pulmonary hypertension |
| GB0708818D0 (en) * | 2007-05-08 | 2007-06-13 | Portela & Ca Sa | Compounds |
| US20110053997A1 (en) * | 2007-12-05 | 2011-03-03 | Alexander Beliaev | Salts and Crystal Forms |
| CA2711160A1 (en) | 2008-01-03 | 2009-07-16 | Biomarin Pharmaceutical Inc. | Pterin analog for treating bh4 responsive condition |
| AR070841A1 (es) * | 2008-03-13 | 2010-05-05 | Bial Portela & Ca Sa | Proceso de hidrogenacion catalitica asimetrica |
| AR071632A1 (es) * | 2008-05-06 | 2010-06-30 | Bial Portela & Ca Sa | Proceso catalitico para hidrogenacion asimetrica en la sintesis de inhibidores de la dopamina-beta-hidroxilasa" |
| DE102008054205A1 (de) * | 2008-10-31 | 2010-05-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Helium-Sauerstoff-Gasgemischen zur Behandlung der pulmonalen arteriellen Hypertonie |
| CN103380128B (zh) * | 2010-12-22 | 2017-03-01 | 拜欧波尔特拉及正大有限公司 | 晶型及其制备方法 |
| DK2919780T3 (en) | 2012-11-14 | 2018-11-26 | Bial Portela & Ca Sa | 1,3-Dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury |
-
2013
- 2013-11-14 DK DK13803292.5T patent/DK2919780T3/en active
- 2013-11-14 ES ES13803292.5T patent/ES2693025T3/es active Active
- 2013-11-14 WO PCT/PT2013/000065 patent/WO2014077715A1/en active Application Filing
- 2013-11-14 PL PL13803292T patent/PL2919780T3/pl unknown
- 2013-11-14 RU RU2015120164A patent/RU2718055C2/ru not_active Application Discontinuation
- 2013-11-14 KR KR1020157014363A patent/KR102259938B1/ko active IP Right Grant
- 2013-11-14 US US14/441,043 patent/US9604970B2/en active Active
- 2013-11-14 JP JP2015542997A patent/JP6373275B2/ja not_active Expired - Fee Related
- 2013-11-14 IN IN4089DEN2015 patent/IN2015DN04089A/en unknown
- 2013-11-14 PT PT13803292T patent/PT2919780T/pt unknown
- 2013-11-14 CA CA2890920A patent/CA2890920C/en not_active Expired - Fee Related
- 2013-11-14 EP EP13803292.5A patent/EP2919780B1/en active Active
- 2013-11-14 RS RS20181204A patent/RS57874B1/sr unknown
- 2013-11-14 TR TR2018/15850T patent/TR201815850T4/tr unknown
- 2013-11-14 MX MX2015005910A patent/MX355422B/es active IP Right Grant
- 2013-11-14 AU AU2013345494A patent/AU2013345494B2/en not_active Ceased
- 2013-11-14 SI SI201331204T patent/SI2919780T1/sl unknown
- 2013-11-14 BR BR112015010969-1A patent/BR112015010969B1/pt not_active IP Right Cessation
- 2013-11-14 LT LTEP13803292.5T patent/LT2919780T/lt unknown
- 2013-11-14 CN CN201380059547.2A patent/CN105025895B/zh not_active Expired - Fee Related
-
2016
- 2016-03-23 HK HK16103398.4A patent/HK1215393A1/zh not_active IP Right Cessation
-
2017
- 2017-02-14 US US15/432,616 patent/US10308640B2/en not_active Expired - Fee Related
-
2018
- 2018-10-11 HR HRP20181651TT patent/HRP20181651T1/hr unknown
- 2018-10-30 CY CY20181101117T patent/CY1120953T1/el unknown
-
2019
- 2019-04-16 US US16/385,350 patent/US20190241545A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021005623A1 (en) * | 2019-07-08 | 2021-01-14 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200626610A (en) | Analogs of 17-hydroxywortmannin as PI3K inhibitors | |
| TW200612958A (en) | Substituted imidazole derivatives | |
| ES2531324T3 (es) | Intermedio para producir un derivado de gamma-aminoácido bicíclico | |
| MX2007004699A (es) | Derivados de indol y bencimidazol. | |
| ATE404536T1 (de) | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin | |
| UA108510C2 (en) | Cyclopropane compound | |
| NZ596615A (en) | Substituted isoquinoline derivative | |
| TW200716084A (en) | Methods for treating sleep-wake disorders | |
| TN2009000287A1 (en) | Cyclized derivatives as eg-5inhibitors | |
| GB0708818D0 (en) | Compounds | |
| MY178106A (en) | 1,4-butanediol-containing composition | |
| UA96947C2 (ru) | Производные циннамоил-пиперазина и их применение как антагонистов par-1 | |
| AR035521A1 (es) | Derivados de 3-indolina y composicion farmaceutica que los comprende | |
| MX2012007896A (es) | Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica. | |
| MX2011008360A (es) | Derivados de piridazinona sustituida con heteroarilo. | |
| PH12015502429A1 (en) | Dicarboxylic acid compound | |
| BR112015011974A2 (pt) | derivados de azaquinazolina carboxamida | |
| EA201001087A1 (ru) | Новые дигидроиндолоновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| MY195881A (en) | Griseofulvin Compound | |
| CY1120953T1 (el) | Παραγωγα 1,3-διυδροϊμιδαζολο-2-θειονης για χρηση στην αγωγη πνευμονικης αρτηριακης υπερτασης και πνευμονικης βλαβης | |
| PE20141168A1 (es) | Derivados de pirazolidin-3-ona | |
| MX2015007424A (es) | Composiciones y/o articulos con solubilidad mejorada de un activo solido. | |
| NO20100192L (no) | Stabile salter av S-adenosylmetionin og fremgangsmater for fremstilling derav | |
| MX2010008196A (es) | Derivados de acido 4-dimetilaminobutirico. | |
| IN2013MN00506A (sr) |